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Abstract
Background: Brain inflammation plays a central role in multiple sclerosis (MS). Dimethylfumarate (DMF), the main 
ingredient of an oral formulation of fumaric acid esters with proven therapeutic efficacy in psoriasis, has recently been 
found to ameliorate the course of relapsing-remitting MS. Glial cells are the effector cells of neuroinflammation; 
however, little is known of the effect of DMF on microglia and astrocytes. The purpose of this study was to use an 
established in vitro model of brain inflammation to determine if DMF modulates the release of neurotoxic molecules 
from microglia and astrocytes, thus inhibiting glial inflammation.
Methods: Primary microglial and astrocytic cell cultures were prepared from cerebral cortices of neonatal rats. The 
control cells were treated with LPS, an accepted inducer of pro-inflammatory properties in glial cells, and the 
experimental groups with LPS and DMF in different concentrations. After stimulation/incubation, the generation of 
nitric oxide (NO) in the cell culture supernatants was determined by measuring nitrite accumulation in the medium 
using Griess reagent. After 6 hours of treatment RT-PCR was used to determine transcription levels of iNOS, IL-1β, IL-6 
and TNF-α mRNA in microglial and astrocytic cell cultures initially treated with DMF, followed after 30 min by LPS 
treatment. Moreover, we investigated possible involvement of the ERK and Nrf-2 transduction pathway in microglia 
using western blot analysis.
Results: Pretreatment with DMF decreased synthesis of the proinflammatory mediators iNOS, TNF-α, IL-1β and IL-6 at 
the RNA level in activated microglia and astrocytes in vitro, associated with a decrease in ERK phosphorylation in 
microglia.
Conclusions: Collectively, these results suggest that the neuroprotective effects of DMF may be in part functionally 
attributable to the compound's ability to inhibit expression of multiple neuroinflammatory mediators in brain of MS 
patients.
Background
Despite growing knowledge regarding its pathogenesis,
and approval of different classes of immunomodulating
drugs, multiple sclerosis (MS), a chronic CNS-disease
characterized by neuroinflammation and demyelination,
remains one of the leading causes of disability in young
adults [1,2]. Approved therapies for MS include inter-
feron-β (IFN-β) and glatiramer acetate as first-line, and
natalizumab and mitoxantrone as second-line [3] treat-
ments. The first-line drugs reduce disease activity and
progression only moderately and the second-line drugs
are characterized by serious possible side effects such as
development of progressive multifocal leukencephalopa-
thy for natalizumab and cardiotoxicity for mitoxantrone.
Moreover, all drugs mentioned above require either sub-
cutaneous or intramuscular (first-line drugs) injections or
intravenous infusions (second-line drugs). Thus, there is
a high demand for orally active, highly efficious drugs
with limited side effects. One such candidate might be
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dimethylfumarate (DMF), which is the active ingredient
of an oral formulation of fumaric acid esters with proven
effectiveness in patients with chronic plaque psoriasis, a
dermatological disorder with immune dysfunction [4,5].
In experimental autoimmune encephalomyelitis (EAE),
an animal model of MS, DMF and its hydrolysis product
monomethylfumarate (MMF) inhibit the disease course,
inhibit macrophage activation in the spinal cord and
increase expression of interleukin-10 [6]. In patients with
relapsing-remitting MS, DMF reduced new inflammatory
lesions in serial MRI-scans in a Phase II trial [7]. These
positive results have led to the initiation of two interna-
tional multi-center double blind and placebo-controlled
Phase III - studies to further test the efficacy of the drug:
Patients are currently recruited for the DEFINE ("deter-
mination of the efficacy and safety of oral fumarate in
relapsing-remitting MS") and the CONFIRM ("compara-
tor and an oral fumarate in relapsing-remitting MS")
studies.
Despite the demonstrated benefits, there are only few
experimental data available concerning DMF-mediated
influences on the glial - especially microglial - environ-
ment in the CNS. This could be of interest because part
of the effect could be mediated via interference with pro-
inflammatory microglia cell functions: In multiple sclero-
sis infiltration of T cells into the nervous system initiates
a complex immunological cascade consisting of epitope
spreading, which triggers new attacks, and activation of
the innate immune system (e.g. microglia, dendritic cells)
which leads to chronic inflammation. Studies using PET-
scans have shown clusters of activated microglia in MS in
vivo [8]. Autopsies studies have shown that diffuse axonal
injury with profound microglia activation is found even
in normal-appearing white matter [9]. Microglia are dis-
tributed throughout the CNS as a network of resting
immunocompetent cells derived from the monocyte/
macrophage lineage. The cells become rapidly activated
in response to injury or in the presence of pathogens and
- like other tissue macrophages in the first line of host
defense - play a pivotal role as phagocytic, antigen-pre-
senting cells. However, it is also this efficient defensive
action that makes them potentially neurotoxic cells. By
releasing various kinds of noxious factors such as proin-
flammatory cytokines (i.e. TNF-α, IL-1β, IL-6) or proin-
flammatory molecules like nitric oxide (NO) microglia
may potentiate damage to CNS cells [10-12]. IL-1β [13]
and NO [14] are expressed in chronic active plaques in
MS patients. NO reacts with superoxide anion to gener-
ate peroxynitrite, a highly reactive molecule capable of
oxidizing proteins, lipids and DNA; and which mediates
microglial toxicity to oligodendrocytes [14] NO can trig-
ger immune cascades that further enhance inflamma-
tory-mediated CNS damage: Increased concentrations of
NO can lead to enhanced expression of chemokine (C-C-
motif) ligand 2 (CCL2) on astrocytes which, in turn, leads
to infiltration of CD11b cells and additional tissue dam-
age [15]. The cytokine TNF-α is an important factor in
the regulation of neuronal apoptotic cell death. TNF-α
mRNA expression in blood mononuclear cells is corre-
lated with disease activity in relapsing-remitting MS
[16,17], while high IL-6 levels in the CNS correlate with
the development of EAE in rats [18]. IL-6 is detected in
acute and chronic active MS plaques from the brain of
patients [19]. Transgenic mice overexpressing IL-6
develop acute neurodegenerative pathology, including
ataxia, tremor and seizures suggestive of a profound
effect of this cytokine on many components of the CNS
[20]. Astrocytes are also producers of a variety of cytok-
ines including IL-1, IL-6 and TNF-α [21].
Given this, there is little doubt that activated glia cells
can inflict significant damage on neighbouring cells in
MS. The effects of DMF in EAE give rise to the hypothe-
sis that the therapeutical benefit of DMF might be at least
partly due to an influence on the glial, especially micro-
glial environment. Our study therefore addresses the
question if DMF might influence the release of the afore-
mentioned inflammatory mediators from activated
microglial cells and astrocytes in vitro. Since nitric oxide
[22] and IL-1β [23] are induced at the protein level in
macrophages and microglia through the activation of
ERK pathway, we moreover investigated if DMF modu-
lates this signalling pathway. Furthermore, the role of
nuclear factor erythroid 2-related factor 2 (Nrf2), a tran-




For all experiments Wistar rats were used, which were
bred and kept under constant conditions (12 h/12 h light/
dark cycle) in the animal house of the University of Kiel.
Microglial cells were prepared from rostral mesenceph-
ali and cerebral hemispheres of 2-day-old Wistar rats
with slight modifications as described previously [24].
Meninges, hippocampi and choroid plexus were removed
from the brains and cortices and mesencephali were
minced, mechanically dissociated by trituration using
fire-polished Pasteur pipettes, followed by enzymatic
digestion with trypsin (from bovine pancreas, type III,
Sigma) and DNAse I (Roche). Suspended mixed brain
cells were plated in culture flask (75 cm2, Sarstedt) in 10
ml growth medium (Dulbecco's modified Eagle's
Medium, DMEM; no. 41965, Invitrogen), supplemented
with 10% (v/v) FBS (fetal bovine serum, Invitrogen), 1%
(v/v) penicillin (10,000 U/ml)/streptomycin (10 mg/ml,
PAA). All cells were cultured in a humidified atmosphere
enriched with 5% CO2. Free floating microglial cells were
collected from the medium of primary cell cultures fromWilms et al. Journal of Neuroinflammation 2010, 7:30
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neonatal rat cerebral cortex after 10 days as detailed else-
where [25].
Prior to replating microglial cells for the different
experiments, cell number and viability was estimated by
trypan-blue exclusion. Viable cells were seeded onto 96-
well-microtiter plates (200,000 cells/well for NO mea-
surement) or 12-well-culture plates (1,000.000 cells/well
for realtime RT-PCR, 1,500.000 cells/well for Western
blot) and grown for 24 hours at 37°C in a humidified
atmosphere enriched with 5% CO2.
Astroglial cell cultures were prepared according to a
slightly modified method of McCarthy and De Vellis [26]
from brains of 2-day-old Wistar rats as described previ-
ously [27]. This method allowed the preparation of nearly
pure cultures of astrocytes with a microglial cell portion,
identified by immunocytochemical OX-42 staining, of
<0.5%. In brief, cerebral hemispheres were freed from the
meninges, the hippocampus, and the choroid plexus. The
cortices were dissociated mechanically (using fire-pol-
ished Pasteur pipettes) and enzymatically (with trypsin
(type III) and DNAse I), and suspended cells were plated
into culture flasks (25 cm2) in growth medium (DMEM
supplemented with 10% (v/v) FBS (56°C heat-inacti-
vated), 1% (v/v) penicillin/streptomycin and 0.1% (v/v)
amphotericin B. For the elimination of neurons, oligo-
dendrocytes and fibroblasts on day 9 in vitro, the culture
flasks were shaken by rotatory shaking (200 rpm, 24 h),
and treatment with 1 μM 5-fluoro-2'-deoxyuridine
(Sigma, Deisenhofen, Germany) for 48 h. Further enrich-
ment in subcultures was obtained by (i) eliminating con-
taminating microglial cells by a preplating procedure, and
(ii) by seeding the cells at low cell density (5000 cells/
cm2), which further reduced the number of contaminat-
ing microglial cells.
Drug treatment
For the induction of microglial activation, lipopolysac-
charide (LPS, 10 ng/ml, from Salmonella typhimurium,
Sigma), a bacterial endotoxin and a generally accepted
inducer of pro-inflammatory properties, was added to the
control groups. The experimental groups were moreover
incubated in the initial experiments with different con-
centrations (1 μM - 100 μM) of DMF (solved in dimethyl-
sulfoxide, DMSO, Sigma), leading to a concentration of
10 μM DMF (= 0,1% DMSO) used in further experi-
ments.
For stimulation experiments the experimental groups
were moreover pre-incubated with 10 μM DMF (30 min-
utes) before LPS was added for a further 6 - 24 hours. The
control groups remained untreated. This concentration
was used since it most probably reflects an appropriate
concentration with regards to the in vivo situation: In
2009 our group detected a level of 5.5 mg/l of the mercap-
turic acid of DMF after oral intake of 240 mg DMF in 24 h
urine of psoriasis patients [28].
PD 98059 was dissolved in DMSO (Sigma) to yield a 10
mM stock solution and was diluted to a final concentra-
tion of 10 μM in the experiments.
Measurement of nitrite production
The nitrite concentration in the culture supernatant was
used as a measure of NO production. After stimulation/
incubation, the generation of NO in the cell culture
supernatants was determined by measuring nitrite accu-
mulation in the medium using Griess reagent (1% sulfa-
nilamide and 0,1% N-(1-naphthyl)-ethylenediamine
dihydrochloride in 5% H3PO4, Sigma, Germany). One
hundred microliters of culture supernatant and 100 μl
Griess reagent were mixed and incubated for 5 minutes.
The absorption was estimated in an automated plate
reader (SLT reader 340 ATTC) at 540 nm. Sodium nitrite
(NaNO2, Merck, Darmstadt) was used to generate a stan-
dard curve for quantification. Background nitrite was
substracted from the experimental value. Results were
obtained from three separate measurements of identically
treated wells/drug, and the data are derived from four
independent experiments.
Quantitative RT-PCR
Microglia and astrocytes were washed three times with
PBS (4°C). RNA was isolated with the TRIZOL reagent,
digested by DNase (Promega, Mannheim, Germany) to
destroy contaminating DNA, and cDNA was synthesized
with RevertAid™ H Minus M-muLV Reverse Tran-
scriptase (Fermentas, St. Leon-Rot, Germany). One
microgram of total RNA was reverse transcribed into 50
ng/μl cDNA by random hexamer primer (no. 27216601,
Amersham Biosciences). Ten nanograms of cDNA were
used for PCR amplification. Quantitative reverse tran-
scriptase PCR was performed in three replicates of each
sample using TaqMan primer probes (Assays on demand;
Applied Biosystems, Foster City, CA, USA) on an ABI
Prism 7000 thermocycler using assays-on-demand and
chemistries as recommended by the manufacturer (all
Applied Biosystems). The PCR signal of the target tran-
script in the treatment groups was related to that of the
control by relative quantification. The 2-ΔΔCT method was
used to analyze the relative changes in gene expression
[29]. The housekeeping gene 18S rRNA was used as inter-
nal control to normalize the PCR for the amount of RNA
added to the reverse transcription reactions and the tar-
get gene expression was normalized to the control. Data
are expressed as percent change of gene expression rela-
tive to LPS-stimulated controls (= 100%).
TaqMan assays had the following identification num-
bers:Wilms et al. Journal of Neuroinflammation 2010, 7:30
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18s: Hs 99999901, iNOS: Rn 00561646, TNFα: Rn
99999017, IL-6: Rn 00561420, IL-1β: Rn 00580432.
Western blotting
For western blot analysis, 750,000 - 1,500,000 microglial
cells were treated with 10 ng/ml LPS in the presence or
absence of 10 ng/ml DMF and after a pre-incubation (30
min.) with PD98059. The cells were washed twice with
PBS, harvested in PBS by scraping, and centrifuged. Cel-
lular protein was isolated from the cell pellet using 100 μl
lysis buffer (128 mM Tris/HCl, 4.6% SDS, 10% glycerine,
0.005% bromphenolblue, 25 μl/ml mercaptoethanol, pH
6.8), boiled for 5 min (95°C), and insoluble material was
removed by centrifugation at 10,000 × g at 4°C for 5 min.
Protein aliquots (5 μg each) were resolved by 12.5% SDS-
PAGE and western blotted with phospho-specific anti-
bodies against ERK1/2 (Cell Signalling Technology, MA,
USA) overnight at 4°C according to the manufacturer's
protocol. For western blot analysis of Nrf2 translocation,
the nuclear fraction of microglia cells was separated using
an NE-PER kit purchased from Pierce, Rockford, IL
(USA). Protein aliquots of lysate (20 μg for Nrf2 and
reloaded with Lamin A/C as loading control) were
detected using a primary antibody against Nrf2 (Santa
Cruz). Antibody binding was detected via enhanced
chemiluminescence (Amersham Pharmacia Biotech,
Essex, UK).
Statistical analysis
All experiments were performed at least three times and
the results presented are from representative experi-
ments. The significance of the difference between experi-
mental and control groups was analyzed using analysis of
variance (ANOVA) followed by the Bonferroni test using
GraphPad Prism 3 Software. An α-level of 0,05 was used
for statistical significance.
Results
Dimethylfumarate reduces mRNA levels of iNOS and NO-
synthesis
Pretreatment of cells with different nontoxic concentra-
tions of DMF before LPS activation led to a significant
and dose-dependent reduction of nitric oxide synthesis in
microglia (Fig. 1A): After 24 hours there was a significant
inhibition (p < 0.001) of LPS-induced increase in nitrite
levels (100%) after cotreatment with dimethyl fumarate
(85,8 ± 0,3%). The suppressive influence of DMF was also
visible at the iNOS mRNA level (73% ± 10,8%) compared
to the LPS control.
Dimethylfumarate reduces mRNA levels of the pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α in microglia
To determine if DMF also suppresses the expression of
IL-1β, IL-6 and TNF-α, real-time RT-PCR analysis was
done. The transcription levels of all investigated cytok-
ines were upregulated after LPS treatment (100%). This
increase was significantly (p < 0.001) inhibited by treat-
ment with dimethyl fumarate for IL-1β (33,4% ± 2,0%),
TNF-α (69,5% ± 4,1%) as well as IL-6 (18,2% ± 3,4%) in
microglia (Fig. 1B).
Astrocytic synthesis of IL-1β, IL-6 and TNF-α is inhibited by 
dimethylfumarate
As demonstrated by real-time PCR, DMF suppresses the
expression of IL-1β, IL-6 and TNF-α mRNA levels in
pure astrocytic cultures. As expected, transcription levels
of all investigated cytokines were upregulated in astro-
glial monocultures used as controls after LPS treatment
(100%). These increases in specific mRNA levels were sig-
nificantly (p < 0.001) inhibited by treatment with DMF
for IL-1β (67,5% ± 8,8%; Fig. 2), IL-6 (65,3% ± 11,2%) as
well as TNF-α (64,5% ± 11,4%). iNOS mRNA was only
moderately and not statistically significant reduced
(71,9% ± 12,5%).
Inhibition of the ERK-pathway is involved in the decreased 
synthesis of proinflammatory microglial molecules induced 
by dimethylfumarate
Considering our findings that DMF inhibited the synthe-
sis of NO, IL-1β, IL-6 and TNF-α in microglial cell cul-
tures, we investigated a possible involvement of the ERK
transduction pathway: Western blot analysis confirmed
that, in comparison to LPS-stimulated microglial cells
used as controls, cotreatment with DMF inhibited phos-
phorylation of ERK by 37,2% (62,9 ± 4,0; Fig. 3).
DMF-induced Nrf2 protein expression
Encouraged by a recent publication [30] about the possi-
ble involvement of Nrf2 in the regulation of neuroinflam-
mation, we analyzed DMF-induced Nrf2 signalling by
western blotting. As shown in Fig. 4, treatment with DMF
caused an increase in Nrf2 protein content in nuclear
extracts of microglia (after 1 h).
Discussion
Dimethylfumarate influences a variety of cell types and
molecules participating in inflammatory conditions.
Clinical studies investigating the mode of action of DMF
in MS show that it depletes CD4+ and CD8+ T cells. This
is caused by the ability of DMF to induce apoptosis in
activated human T-cells [31].
Moreover, there is a shift from Th1- to Th2-cells
regarding cytokine production: While the "Th1 pattern"
is characterized by a proinflammatory response with
increased synthesis of interleukin (IL) 2, TNF-α and IFN-
γ; the cytokines IL-4, IL-5 and IL-10 are produced by
Th2-cells [32].
While the inflammatory infiltrate in active MS lesions
consists mostly of a perivascular accumulation of CD4+Wilms et al. Journal of Neuroinflammation 2010, 7:30
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and CD8+ T cells and B cells, it eventually includes micro-
glia in the lesion center that stain positively for ingested
myelin (for review see [33]). More pieces of evidence for
microglial activation early in the disease course come
from autopsy studies of patients suffering from relapsing-
remitting MS, who died during or shortly after a relapse:
Activated microglia and apoptotic oligodendrocytes are
found in the absence of leukocytes [34]. Many of the stud-
ies regarding CNS adaptive immunity have focused on
hematopoietically-derived microglia, which are able to
take up antigens and present them to T cells.
Although they are derived from neuroectodermal lin-
eage, astrocytes also function as antigen-presenting cells.
Astrocytes express major histocompatibility complex
(MHC) class I and class II molecules in vitro [35]. Func-
tional studies indicate that IFN-γ-treated astrocytes are
able to activate both CD8+ [36] and CD4+ T cells [37].
Astrocytes also have the potential to secrete inflamma-
tory cytokines such as IL-1β, IL-6, and TNF-α [21]:
Because the disease is initiated by T cells, it is likely that
astrocytes are activated to release cytokines in response
to T cell-derived factors and therefore, would perpetuate
immune-mediated demyelination.
Figure 1 Dimethyl fumarate inhibits LPS-induced mRNA expression of NO (A), iNOS, Il-1β, Il-6 and TNF-α (B), respectively, in cultivated mi-
croglia. LPS was added to microglia cells 30 min after the addition of dimethyl fumarate (10 μM) to analyze its effect on mRNA expression after 6 hours 
of treatment. mRNA expression was analyzed using TaqMan real-time RT-PCR and results for cells treated with dimethyl fumarate were compared to 
those of cells stimulated solely by LPS. 18s RNA (a housekeeping gene) was used as an internal control. The data were assessed from 3 independent 
experiments, each run in triplicate. Asterisks (* = p < 0.05; *** = p < 0.001), indicate significant differences compared to cells stimulated solely by LPS 
(ANOVA followed by the Bonferroni test).Wilms et al. Journal of Neuroinflammation 2010, 7:30
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In this study we examined how DMF influences micro-
glial and astroglial cells in vitro. To induce microglial and
astroglial activation, LPS, a bacterial endotoxin and gen-
erally accepted inducer of pro-inflammatory properties,
was added to experimental and positive control groups.
In an animal model of MS local injection of LPS induces
microglial activation through toll-like receptors (TLR)
resulting in inflammatory demyelinating plaques [38].
A major finding of this study is that DMF negatively
regulates the synthesis of NO in microglia and astrocytes
in vitro as compared to LPS-activated positive controls.
Expression of inducible NO synthase is abundant at the
edges of MS lesions [14]. NO reacts with superoxide to
from peroxynitrite, a marker for the formation of reactive
nitrogen species, which nitrosylates amine and sulphate
side groups on proteins and lipids. Nitrolysine is recog-
nized as a marker of myelin damage and is found in MS
plaques as well.
Activated microglia [12] and astrocytes [21] can release
TNF-α, which is a potent pro-inflammatory cytokine,
and blockage of microglia-dependant TNF-α delivery
suppresses inflammation and demyelination in EAE [39].
It is noteworthy that in our in vitro model DMF reduced
the synthesis of TNF-α, IL-1β and IL-6 in LPS-activated
microglia and astrocytes as well. Ingestion of myelin
debris by microglia is a pathological hallmark of active
MS lesions. In adult humans, microglia that are actively
phagocytising myelin vesicles secrete proinflammatory
cytokines (TNF-α, IL-1β and IL-6) and undergo oxidative
bursts [40]. These data are substantiated by recent find-
ings using cytokine-stimulated airway smooth muscle
cells after TNF-α-stimulation. While Seidel et al. [41]
showed a significant reduction of IL-6 by DMF in a dose-
dependent fashion which was due to inhibition of
nuclear-factor-kappa B (NF-κB), we decided to assess a
possible influence of DMF on Nrf2. The activation of
Figure 2 Dimethyl fumarate inhibits LPS-induced mRNA expression of iNOS (A), Il-1β (B), Il-6 (C) and TNF-α (D) in astrocytes. LPS was added 
to astrocytes 30 min after the addition of dimethylfumarate (10 μM), its effect on mRNA expression was analyzed after 6 hours of treatment. mRNA 
expression was analyzed using TaqMan real-time RT-PCR and results for cells treated with dimethyl fumarate were compared to those of cells stimu-
lated solely by LPS. 18s RNA (a housekeeping gene) was used as an internal control. The data were assessed from 3 independent experiments, each 
run in triplicate. Asterisks (* = p < 0.05; ** = p < 0,01), indicate significant differences compared to cells stimulated solely by LPS (ANOVA followed by 
the Bonferroni test). Note that the reduction of iNOS mRNA (Fig. 3A) is not statistically significant.Wilms et al. Journal of Neuroinflammation 2010, 7:30
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Nrf2, a transcription factor possibly involved in neuro-
protective responses (for recent review see [42]), sup-
ports the notion that Nrf2 is involved in the anti-
inflammatory activity of DMF and, therefore, could be a
promising new potential therapeutic target.
Summarizing our findings, DMF, which exerts anti-
inflammatory as well as Nrf2-activating properties, might
positively influence the course of relapsing-remitting MS
by inhibiting microglial and astroglial activation and sub-
sequent release of pro-inflammatory neurotoxic media-
tors. Oral formulations of disease-modifying drugs have
advantages in convenience and will be preferred by most
patients. However, we will have to await the results from
ongoing large phase III trials to establish the place of
DMF in the treatment of MS.
Conclusion
We demonstrate that DMF inhibits a proinflammatory
response characterised by increased microglial and astro-
cytic synthesis of NO, IL-1, IL-6 and TNF-α in an in vitro
model of brain inflammation. The microglial mechanism
involves the ERK transduction pathway and the activa-
tion of Nrf2, and may be highly relevant to the neuropro-
tective effect of DMF in MS.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HW initiated the project and wrote the paper. JS participated in the design of
the study and prepared the cell cultures. UR is a post doctoral fellow who
orchestrated and carried out the work with the help of MRY. UM carried out the
RT-PCR and helped to draft the manuscript. RL is the Principal Investigator and
Head of the laboratory and the group, and conceptualized the experiments. All
authors have read and approved the final manuscript.
Acknowledgements
The authors would like to thank Mrs. Rosemarie Sprang for superior technical 
assistance. This work was supported by the DFG Excellence Cluster "Inflamma-
tion at Interfaces" (to RL) and a generous donation from the "Herbert und Inge 
Lampe Stiftung" (to HW and RL).
Author Details
1Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 
400, 69120 Heidelberg, Germany, 2Department of Anatomy, Olshausenstr. 40, 
University of Kiel, D-24098 Kiel, Germany and 3Psoriasis-Center, Department of 
Dermatology, Venereology, and Allergology University Medical Center 
Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 7, D-24105 Kiel, 
Germany
References
1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple 
sclerosis.  N Engl J Med 2000, 343:938-952.
2. Frohman EM, Racke MK, Raine CS: Multiple sclerosis--the plaque and its 
pathogenesis.  N Engl J Med 2006, 354:942-955.
3. Wingerchuk DM: Current evidence and therapeutic strategies for 
multiple sclerosis.  Semin Neurol 2008, 28:56-68.
4. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, 
Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi RK: 
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter 
Received: 2 February 2010 Accepted: 19 May 2010 
Published: 19 May 2010
This article is available from: http://www.jneuroinflammation.com/content/7/1/30 © 2010 Wilms et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Neuroinflammation 2010, 7:30
Figure 3 DMF inhibition of ERK phosphorylation in LPS-activated 
microglia. Results are compared to microglial cultures stimulated 
solely by LPS. Results are detected by western blot after 5 minutes of 
treatment. Activated ERK (phospho-ERK) species were detected by im-
munoblot analysis with antibodies specific for the phosphorylated 
forms of the kinase (A). The amount of protein loaded in each lane was 
confirmed by measurement of the amount of ERK using antibody 
against the unphosphorylated form of ERK. (B) Blots were subjected to 
densitometry and normalized to the signal of the respective pan-MAPK 
antibody. Results are representative of 3 independent experiments (*** 
= p < 0.001).
Figure 4 DMF-induced expression of Nrf2 protein in microglia. 
One hour after stimulation of microglia with DMF, nuclear proteins 
were isolated and separated using SDS-polyacrylamide gel electro-
phoresis, western blotted and probed with anti-Nrf2, and reprobed 
with anti-Lamin A/C (as a loading control) antibodies.Wilms et al. Journal of Neuroinflammation 2010, 7:30
http://www.jneuroinflammation.com/content/7/1/30
Page 8 of 8
double-blind study in 100 patients.  J Am Acad Dermatol 1994, 
30:977-981.
5. Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis 
with fumaric acid esters: scientific background and guidelines for 
therapeutic use. The German Fumaric Acid Ester Consensus 
Conference.  Br J Dermatol 1999, 141:424-429.
6. Schilling S, Goelz S, Linker R, Luehder F, Gold R: Fumaric acid esters are 
effective in chronic experimental autoimmune encephalomyelitis and 
suppress macrophage infiltration.  Clin Exp Immunol 2006, 145:101-107.
7. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, 
Polman CH, Schmierer K, Yousry TA, Yang M, for the BG-12 Phase IIb Study 
Investigators: Efficacy and safety of oral fumarate in patients with 
relapsing-remitting multiple sclerosis: a multicentre, randomised, 
double-blind, placebo-controlled phase IIb study.  Lancet 2008, 
372:1463-1472.
8. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, 
Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson 
AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R: The 
peripheral benzodiazepine binding site in the brain in multiple 
sclerosis: quantitative in vivo imaging of microglia as a measure of 
disease activity.  Brain 2000, 123:2321-2337.
9. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, 
Bergmann M, Schmidbauer M, Parisi JE, Lassmann H: Cortical 
demyelination and diffuse white matter injury in multiple sclerosis.  
Brain 2005, 128:2705-2712.
10. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW: Cytotoxicity of 
microglia.  Glia 1993, 7:111-118.
11. Giulian D, Corpuz M: Microglial secretion products and their impact on 
the nervous system.  Adv Neurol 1993, 59:315-320.
12. McGeer PL, McGeer EG: The inflammatory response system of brain: 
implications for therapy of Alzheimer and other neurodegenerative 
diseases.  Brain Res Brain Res Rev 1995, 21:195-218.
13. Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE: 
Immunoregulatory molecules and IL 2 receptors identified in multiple 
sclerosis brain.  J Immunol 1986, 136:3239-3245.
14. Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW: Inducible nitric oxide 
synthase in chronic active multiple sclerosis plaques: distribution, 
cellular expression and association with myelin damage.  J 
Neuroimmunol 2004, 151:171-179.
15. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, 
Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL: Reversal 
of axonal loss and disability in a mouse model of progressive multiple 
sclerosis.  J Clin Invest 2008, 118:1532-1543.
16. Navikas V, He B, Link J, Haglund M, Soderstrom M, Fredrikson S, Ljungdahl 
A, Hojeberg J, Qiao J, Olsson T, Link H: Augmented expression of tumour 
necrosis factor-alpha and lymphotoxin in mononuclear cells in 
multiple sclerosis and optic neuritis.  Brain 1996, 119(Pt 1):213-223.
17. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, 
Helwig A, Poser S: Tumor necrosis factor-alpha messenger RNA 
expression in patients with relapsing-remitting multiple sclerosis is 
associated with disease activity.  Ann Neurol 1995, 37:82-88.
18. Diab A, Zhu J, Xiao BG, Mustafa M, Link H: High IL-6 and low IL-10 in the 
central nervous system are associated with protracted relapsing EAE in 
DA rats.  J Neuropathol Exp Neurol 1997, 56:641-650.
19. Maimone D, Guazzi GC, Annunziata P: IL-6 detection in multiple sclerosis 
brain.  J Neurol Sci 1997, 146:59-65.
20. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, 
Mucke L: Neurologic disease induced in transgenic mice by cerebral 
overexpression of interleukin 6.  Proc Natl Acad Sci USA 1993, 
90:10061-10065.
21. Dong Y, Benveniste EN: Immune function of astrocytes.  Glia 2001, 
36:180-190.
22. Blanchette J, Jaramillo M, Olivier M: Signalling events involved in 
interferon-gamma-inducible macrophage nitric oxide generation.  
Immunology 2003, 108:513-522.
23. Lu K, Cho CL, Liang CL, Chen SD, Liliang PC, Wang SY, Chen HJ: Inhibition 
of the MEK/ERK pathway reduces microglial activation and interleukin-
1-beta expression in spinal cord ischemia/reperfusion injury in rats.  J 
Thorac Cardiovasc Surg 2007, 133:934-941.
24. Wilms H, Schwabedissen B, Sievers J, Lucius R: Erythropoietin does not 
attenuate cytokine production and inflammation in microglia--
implications for the neuroprotective effect of erythropoietin in 
neurological diseases.  J Neuroimmunol 2009, 212:106-111.
25. Lucius R, Sievers J, Mentlein R: Enkephalin metabolism by microglial 
aminopeptidase N (CD13).  J Neurochem 1995, 64:1841-1847.
26. McCarthy KD, de Vellis J: Preparation of separate astroglial and 
oligodendroglial cell cultures from rat cerebral tissue.  J Cell Biol 1980, 
85:890-902.
27. Lucius R, Sievers J: Postnatal retinal ganglion cells in vitro: protection 
against reactive oxygen species (ROS)-induced axonal degeneration 
by cocultured astrocytes.  Brain Res 1996, 743:56-62.
28. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U: 
Detection of metabolites of fumaric acid esters in human urine: 
implications for their mode of action.  J Invest Dermatol 2009, 
129:231-234.
29. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.  
Methods 2001, 25:402-408.
30. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto 
M, Cuadrado A: Nrf2 regulates microglial dynamics and 
neuroinflammation in experimental Parkinson's disease.  Glia 
58:588-598.
31. Treumer F, Zhu K, Glaser R, Mrowietz U: Dimethylfumarate is a potent 
inducer of apoptosis in human T cells.  J Invest Dermatol 2003, 
121:1383-1388.
32. de Jong R, Bezemer AC, Zomerdijk TP, Pouw-Kraan T van de, Ottenhoff TH, 
Nibbering PH: Selective stimulation of T helper 2 cytokine responses by 
the anti-psoriasis agent monomethylfumarate.  Eur J Immunol 1996, 
26:2067-2074.
33. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan 
C: Multiple sclerosis.  Immunol Rev 2005, 204:208-231.
34. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: 
pathology of the newly forming lesion.  Ann Neurol 2004, 55:458-468.
35. Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW: Inducible 
expression of H-2 and Ia antigens on brain cells.  Nature 1984, 
310:688-691.
36. Sedgwick JD, Mossner R, Schwender S, ter Meulen V: Major 
histocompatibility complex-expressing nonhematopoietic astroglial 
cells prime only CD8+ T lymphocytes: astroglial cells as perpetuators 
but not initiators of CD4+ T cell responses in the central nervous 
system.  J Exp Med 1991, 173:1235-1246.
37. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett 
TA, Miller SD: IFN-gamma-activated primary murine astrocytes express 
B7 costimulatory molecules and prime naive antigen-specific T cells.  J 
Immunol 1997, 158:614-621.
38. Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, 
Smith KJ: Inflammation and primary demyelination induced by the 
intraspinal injection of lipopolysaccharide.  Brain 2005, 128:1649-1666.
39. Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H: TNF-
alpha receptor fusion protein prevents experimental auto-immune 
encephalomyelitis and demyelination in Lewis rats: an overview.  J 
Neuroimmunol 1997, 72:163-168.
40. Williams K, Ulvestad E, Waage A, Antel JP, McLaurin J: Activation of adult 
human derived microglia by myelin phagocytosis in vitro.  J Neurosci 
Res 1994, 38:433-443.
41. Seidel P, Merfort I, Hughes JM, Oliver BG, Tamm M, Roth M: 
Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to 
limit airway smooth muscle cell cytokine secretion.  Am J Physiol Lung 
Cell Mol Physiol 2009, 297:L326-339.
42. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J: The transcription 
factor Nrf2 as a new therapeutic target in Parkinson's disease.  Expert 
Opin Ther Targets 2009, 13:319-329.
doi: 10.1186/1742-2094-7-30
Cite this article as: Wilms et al., Dimethylfumarate inhibits microglial and 
astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1?, 
TNF-? and IL-6 in an in-vitro model of brain inflammation Journal of Neuroin-
flammation 2010, 7:30